FluoroPharma Medical, Inc. (FPMI)
FluoroPharma Medical, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Montclair, NJ, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $6,852. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of 0.0%. Its beta of 0.09 implies it has historically moved less than the broad market.
FluoroPharma Medical, Inc. (FPMI) is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of advanced molecular imaging agents. Initially, its efforts are concentrated on cardiovascular applications within the United States market. The company's pipeline features two notable product candidates: BFPET: An imaging agent designed for stress-testing patients with suspected or confirmed coronary artery disease (CAD), which has successfully completed its Phase I clinical trial. CardioPET: Another molecular imaging agent, currently undergoing a Phase IIa clinical trial. This compound aims to evaluate myocardial blood flow and metabolism in individuals afflicted with CAD. FluoroPharma Medical has established key collaborations, including licensing agreements with Massachusetts General Hospital and Sinotau USA. Furthermore, the company holds clinical research agreements with Pharmaceutical Product Development, LLC, and Cardiovascular Imaging Technologies. Established in 2003, FluoroPharma Medical, Inc. is headquartered in Montclair, New Jersey.
FluoroPharma Medical, Inc. is most often compared with the following Healthcare names: